Live Workshop

Collaborative Learning Workshops to Examine Best Practices for Implementing Cancer Immunotherapies in the Community

This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.

Target Audience

This initiative aims to provide guidance for oncologists; oncology nurse practitioners, physician assistants, nurses, and other healthcare professionals who are involved in the care of patients with cancer in the community setting, on the practical issues related to the optimal integration of immunotherapies to treat cancer. 

Overview

According to the National Cancer Institute, 80% of cancer patients are treated in community hospitals each year in the US. Community oncologists treat several types of cancers and see a large volume of patients. Community clinicians may also lack familiarity with the evidence supporting the use of immunotherapies to treat patients with cancer and the novel and unique toxicities that are associated with these relatively new class of drugs. There is a need to provide guidance on the best practices for overcoming barriers in the community setting to integrating immunotherapies into practice, including communication and coordination within the cancer care team especially with other specialists who may be treating these patients for other comorbidities. Immunotherapies are associated with a unique set of immune-related adverse events (irAEs) and it is crucial to monitor and manage them across the continuum of care to ensure prompt diagnosis and optimal management of these complications. This initiative will provide guidance on key issues related to the optimal integration of cancer immunotherapies in the community, including coordination and communication within the multidisciplinary care team, coverage, and reimbursement, and patient education and engagement, to the entire cancer care team in the community settings. The initiative will discuss the latest clinical data for immunotherapies in non-small cell lung cancer (NSCLC), bladder cancer and melanoma.

Objectives

At the end of this educational initiative, participants should be able to:

• Apply evidence-based practices for selection of immunotherapies in NSCLC, bladder cancer, and melanoma.
• Discuss the nuance of administering immunotherapies with respect to response kinetics and immune-related adverse events in NSCLC, bladder cancer, and melanoma.
• Evaluate tools and resources for monitoring and managing immune-related adverse events in NSCLC, bladder cancer, and melanoma.
• Examine solutions for improving coordination and communication within the multidisciplinary care team and with patients and caregivers to improve outcomes for patients receiving immunotherapies.
• Review strategies for improving coverage and access to immunotherapies in the community setting. 

If your site in interested in participating, please contact Christina Mangir, MS, Program Manager, ACCC Provider Education

Agenda

Faculty

Missak Haigentz, Jr., MD
Section Chief, Hematology/Oncology
Chair, Cancer Committee
Morristown Medical Center/Atlantic Health System
Morristown, NJ

Ari VanderWalde, MD, MPH, FACP
Director of Clinical Research, West Cancer Center
Associate Vice Chancellor of Research
Assistant Professor, Division of Hematology/Oncology,
The University of Tennessee Health Science Center
Memphis, TN

Laura Wood, RN, MSN, OCN
Renal Cancer Research Coordinator
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH

Sarah Hudson-DiSalle, PharmD, RPh
Oncology Pharmacy Manager
Wexner Medical Center and James Cancer Hospital
Columbus, OH

CONTINUING EDUCATION

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 4.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points. 

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 4.0 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information

For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Disclaimer  

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit 

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing and returning the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be emailed to you within 3 weeks.